The news: US News & World Report launched ratings of telehealth platforms offering GLP-1 weight loss drugs. The report evaluated 20 online platforms that prescribe FDA-approved, brand-name GLP-1 medications to help consumers navigate their options. Companies were assessed using thousands of data points on their platforms and feedback from 1,200+ consumers who access GLP-1s via telehealth.

Digging into the ratings: Platforms were scored on a 5-point scale across six key pillars: clinical support (25%), screening rigor (20%), transparency (17%), insurance assistance (15%), supplemental care (13%), and overall customer satisfaction (10%).

• Overall winner: Amazon One Medical with a 4.8/5
• Best for insurance support: Amazon One Medical, based on its concierge-provided insurance assistance and FSA/HSA acceptance.
• Best for clinical support: Found, based on its access to video appointments with the originally matched clinician, baseline lab work, and support for managing side effects.
• Best for supplemental support: Noom, based on the availability and quality of its mental health, nutrition, and diet advice; online community access; and progress-tracking tools.
• Best for customer satisfaction: Ro, based on customer-reported experiences and their likelihood to recommend the company.

Why it matters: More consumers will expect GLP-1 care to go beyond prescription access.

While convenient online prescribing remains important, longer-term users are likely to seek more comprehensive clinical and lifestyle support, including ongoing provider care, side-effect management, and nutrition guidance as their appetite and dietary needs evolve. They’ll also look for help navigating costs and financial resources, as price is a top driver of treatment discontinuation.

Many GLP-1 patients currently lack ongoing health guidance and assistance planning for high medication costs or anticipating changes in insurance coverage. Diet-related advice typically emphasizes calorie reduction over comprehensive nutritional support, according to a study published earlier this year. A May PwC survey found that current and former users are piecing together routines from a fragmented mix of information, tools, and services, often without consistent professional advice to manage treatment and lifestyle changes. Meanwhile, nearly half of GLP-1 patients said their medication cost was more expensive than expected, per a February 2026 Navitus Health Solutions survey.

Implications for GLP-1 brands and marketers: The rapid expansion of telehealth has made obtaining a weight loss drug prescription easier than ever. Over one-quarter (26%) of GLP-1 patients, including 55% of Gen Zers, have used a telehealth service to get their prescription, per January 2026 EMARKETER survey data.

At the same time, GLP-1 telehealth brands are now entering a new phase of scrutiny, where access alone is no longer enough to differentiate. As the market matures, third-party benchmarks can shift competition toward quality of care and the broader patient experience—elevating expectations for what consumers expect from digital weight loss providers. Similar to US News & World Report’s university and hospital ratings, GLP-1 telehealth rankings could provide a standardized way to compare providers on care quality, reputation, patient experience, and affordability, shaping decisions among consumers, employers, and insurers.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.